Literature DB >> 6773975

Multiple abnormalities of anterior pituitary hormone secretion in association with pseudohypoparathyroidism.

M S Shapiro, J Bernheim, A Gutman, I Arber, I M Spitz.   

Abstract

A male with pseudohypoparathyroidism presented with several hormonal abnormalities. He was clinically euthyroid with no palpable goiter, His serum T4, total T3, T3 Sephadex retention, and 131I uptake were normal. However, elevated basal TSH levels and exaggerated TSH responses to TRH which normalized during the administration of thyroid extract suggested reduced thyroidal reserve. Despite these finding the 131I uptake increased after exogeneous TSH, and the T3 level rose after TRH. Basal testosterone levels and response to hCG were normal however, gonadotropins were elevated and there was an exaggerated response after LRH treatment. Both LH and FSH levels were suppressed by testosterone propionate. The patient demonstrated intermittent basal hyperprolactinemia and impaired PRL responsiveness after metolopramide, chlorpromazine, and insulin administration. There was, however, an intact response to TRH. Basal PRL, TSH, and LH levels decreased after the administration of L-dopa and bromocriptine. Although the precise mechanism underlying these finding is unknown, the elevated basal levels of TSH, LH, and FSH and the exaggerated responses to their respective releasing hormones suggest the presence of partial degree of end-organ resistance to these pituitary trophic hormones. Together with the resistance to PTH, this may imply a common defect, presumably at a postreceptor level. However, hyporesponsiveness of PRL to metoclopramide and chlorpromazine and normal responsiveness to TRH suggest that an abnormality of dopamine tone also exists in pseudohypoparathyroidism.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6773975     DOI: 10.1210/jcem-51-3-483

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  5 in total

1.  Familial growth hormone releasing factor deficiency in pseudopseudohypoparathyroidism.

Authors:  H F Stirling; D G Barr; C J Kelnar
Journal:  Arch Dis Child       Date:  1991-04       Impact factor: 3.791

2.  Impaired formation of beta-adrenergic receptor-nucleotide regulatory protein complexes in pseudohypoparathyroidism.

Authors:  J A Heinsimer; A O Davies; R W Downs; M A Levine; A M Spiegel; M K Drezner; A De Lean; K A Wreggett; M G Caron; R J Lefkowitz
Journal:  J Clin Invest       Date:  1984-05       Impact factor: 14.808

3.  Multiple associated endocrine abnormalities in a patient with pseudohypoparathyroidism type 1a.

Authors:  M Shima; O Nose; K Shimizu; Y Seino; H Yabuuchi; T Saito
Journal:  Eur J Pediatr       Date:  1988-06       Impact factor: 3.183

4.  Pseudohypoparathyroidism type Ia: two new heterozygous frameshift mutations in exons 5 and 10 of the Gs alpha gene.

Authors:  H Shapira; M Mouallem; M S Shapiro; Y Weisman; Z Farfel
Journal:  Hum Genet       Date:  1996-01       Impact factor: 4.132

5.  Pseudopseudohypoparathyroidism associated with idiopathic growth hormone deficiency. Role of treatment with biosynthetic growth hormone.

Authors:  R Manfredi; A Zucchini; L Azzaroli; G Manfredi
Journal:  J Endocrinol Invest       Date:  1993-10       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.